The p42/p44 mitogen-activated protein kinase activation triggers p27Kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells

被引:56
作者
Delmas, C
Manenti, S
Boudjelal, A
Peyssonnaux, C
Eychène, A
Darbon, JM
机构
[1] Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat, CNRS, UMR 5088, F-31062 Toulouse, France
[2] Inst Curie, CNRS, UMR 146, Lab 110, F-91405 Orsay, France
关键词
D O I
10.1074/jbc.M101714200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p42/p44 mitogen-activated protein (MAP) kinase is stimulated by various mitogenic stimuli, and its sustained activation is necessary for cell cycle G(1) progression and G(1)/S transition. G(1) progression and G(1)/S transition also depend on sequential cyclin-dependent kinase (CDK) activation. Here, we demonstrate that MAP kinase inhibition leads to accumulation of the CDK inhibitor P27(Kip1) in NIH 3T3 cells. Blocking the proteasome-dependent degradation of p27(Kip1) impaired this accumulation, suggesting that MAP kinase does not act on p271(Kip1) protein synthesis. In the absence of extracellular signals (growth factors or cell adhesion), genetic activation of MAP kinase decreased the expression of P27(Kip1) as assessed by cotransfection experiments and by immunofluorescence detection. Importantly, MAP kinase activation also decreased the expression of a p27(Kip1) mutant, which cannot be phosphorylated by CDK2, suggesting that MAP kinase-dependent p27(Kip1) regulation is CDK2-independent. Accordingly, expression of dominant-negative CDK2 did not impair the down-regulation of p27(Kip1) induced by MAP kinase activation. These data demonstrate that the MAP kinase pathway regulates p27(Kip1) expression in fibroblasts essentially through a degradation mechanism, independently of p27(Kip1) phosphorylation by CDK2. This strengthens the role of this CDK inhibitor as a key effector of G(1) growth arrest, whose expression can be controlled by extracellular stimuli-dependent signaling pathways.
引用
收藏
页码:34958 / 34965
页数:8
相关论文
共 60 条
[1]  
Agrawal D, 1996, MOL CELL BIOL, V16, P4327
[2]   The extracellular matrix and mitogenic growth factors control G1 phase cyclins and cyclin-dependent [J].
Bottazzi, ME ;
Assoian, RK .
TRENDS IN CELL BIOLOGY, 1997, 7 (09) :348-352
[3]   Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27KIP1 independent of MAPK activity [J].
Busse, D ;
Doughty, RS ;
Ramsey, TT ;
Russell, WE ;
Price, JO ;
Flanagan, WM ;
Shawver, LK ;
Arteaga, CL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (10) :6987-6995
[4]   SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 [J].
Carrano, AC ;
Eytan, E ;
Hershko, A ;
Pagano, M .
NATURE CELL BIOLOGY, 1999, 1 (04) :193-199
[5]   G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY 294002 is correlated to up-regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells [J].
Casagrande, F ;
Bacqueville, D ;
Pillaire, MJ ;
Malecaze, F ;
Manenti, S ;
Breton-Douillon, M ;
Darbon, JM .
FEBS LETTERS, 1998, 422 (03) :385-390
[6]   Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1) [J].
Cheng, MG ;
Sexl, V ;
Sherr, CJ ;
Roussel, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (03) :1091-1096
[7]   Requirement of p27(Kip1) for restriction point control of the fibroblast cell cycle [J].
Coats, S ;
Flanagan, WM ;
Nourse, J ;
Roberts, JM .
SCIENCE, 1996, 272 (5263) :877-880
[8]   Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1 [J].
Collado, M ;
Medema, RH ;
García-Cao, I ;
Dubuisson, MLN ;
Barradas, M ;
Glassford, J ;
Rivas, C ;
Burgering, BMT ;
Serrano, M ;
Lam, EWF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (29) :21960-21968
[9]   Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity [J].
Eymin, B ;
Sordet, O ;
Droin, N ;
Munsch, B ;
Haugg, M ;
Van de Craen, M ;
Vandenabeele, P ;
Solary, E .
ONCOGENE, 1999, 18 (34) :4839-4847
[10]  
GANG W, 1999, ONCOGENE, V18, P5204